Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced ...

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

During exercise, increased blood flow to capillaries raises red blood cell velocity and local capillary hematocrit ... are due to impaired blood flow rather than direct muscle pathology. 46 These data ...

Prof. MENG Guangxun's team from the Shanghai Institute of Immunity and Infection of the Chinese Academy of Sciences, and collaborators, have revealed a novel mechanism whereby a short form of IL-18, ...

Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...

This study on mouse Ly49 receptors expressed on natural killer (NK) cells shows that Ly49A, in the presence of the corresponding MHC Class I allele, can lead to NK cell licensing, thereby providing ...

Normal T-cells express CD5 but NK (natural killer) cells do not, positioning NK cells as attractive cytotoxicity cells for CD5CAR design. Additionally, CD5 is highly expressed in T-cell acute ...